The Saudi Food and Drug Authority (SFDA) regulates food, drugs, medical devices and cosmetics in the Kingdom of Saudi Arabia. For a pharmaceutical or nutraceutical brand entering the market, SFDA is the single authority that decides whether a product may be sold — and under which set of rules.
Raised Pharma supports manufacturers and brand owners preparing for the Saudi market from our offices in Canada, the USA and India: product classification, dossier preparation, GMP evidence, stability data and Arabic labelling review.
This is where most Saudi projects are won or lost, and it surprises almost every first-time applicant.
SFDA does not classify a supplement by what you call it. Under SFDA’s published Products Classification Guidance, the same formula can be regulated by the Food Sector or the Drug Sector depending on two things:
The practical consequences:
Those three outcomes mean different registrants, different dossiers and very different evidence burdens. Changing one sentence on your label, or one milligram in your formula, can move your product between them.
A note for Canadian clients: there is no direct Saudi equivalent of a Canadian NPN. A product holding an NHP licence in Canada may map to either a Saudi food supplement or a Saudi health product. Do not assume the Canadian classification carries across.
Drugs, herbal and health products — SFDA works to the GCC-harmonised data requirements built on the CTD structure. Its published submission guidance specifies eCTD format for human products and CTD for herbal and health products. Module 1 carries the regional content, including a Certificate of a Pharmaceutical Product (or, where unavailable, a marketing authorisation or free sale certificate from the country of origin), a valid GMP certificate, labelling, patient information leaflet and artwork, pharmacovigilance documentation, and pricing information benchmarked against a basket of reference countries.
Food supplements — a lighter but still demanding route. The establishment or importer is registered first, then the product, with label artwork, a technical data sheet quantifying ingredients, certificate of analysis, free sale certificate and stability data supporting the declared shelf life. Certain categories, including food supplements, require a pre-registration evaluation.
One detail that catches nutraceutical brands out: while SFDA accepts GMP, HACCP or ISO 22000 certification for food supplements generally, pharmaceutical-grade GMP is expected for capsule, tablet and pill dosage forms. A supplement made on a food-grade line may not clear this. This is precisely the gap a pharmaceutical CDMO exists to close.
Under SFDA’s Registration Rules, foreign companies that do not hold a Saudi commercial investment licence from the Ministry of Investment must appoint an agent — and the requirement is expressed per product, not as a single blanket appointment. Foreign manufacturers generally cannot submit to SFDA’s drug registration system directly.
On the food side the mechanism differs: a registered Saudi food establishment or importer must exist before any product can be registered, and that entity is the registrant — not the foreign manufacturer.
The exact conditions an agent must satisfy, and how the agency relationship is recorded, should be confirmed with SFDA and Saudi legal counsel before you commit. Agency arrangements in the Gulf are often harder to exit than to enter.
For food and supplements, Arabic labelling is mandatory, following the applicable GSO prepackaged food labelling standards. Where other languages appear, the information must match the Arabic.
For drugs the position is more specific than most summaries suggest: SFDA requires Arabic for defined label components — product name and strength, dosage form and pack size, storage conditions, manufacturer and marketing authorisation holder — and the patient information leaflet in both Arabic and English. Full-label Arabic is normal for retail products, but the guidance is component-specific rather than blanket.
Halal certification applies to products containing ingredients of animal origin, or bearing the term Halal. For nutraceutical formulations this reaches further than people expect: gelatin capsules, collagen, glycerin and certain excipients all become dossier questions.
SFDA also prohibits stating or implying on a label that a product is “licensed by SFDA”, and prohibits use of the SFDA logo. Only the reference number may be shown.
SFDA’s own regulatory framework documents the common failure points, and one deserves emphasis:
We do not publish approval timelines for Saudi Arabia, and we would be cautious of anyone who does. SFDA publishes target review clocks by registration route, but those measure the authority’s assessment time — not elapsed calendar time to approval, and not the time your own team spends answering deficiency questions. Dossier quality is the variable you actually control. Current timelines and fees must be confirmed with SFDA at the time of application.
Tell us the product, the dosage form, the claims you want to make and the stage you are at, and we will tell you plainly whether Saudi Arabia is a straightforward market for it or a difficult one.
Email: info@raisedpharma.com Phone: +1 (716)-777-4800
Request a consultation See all GCC markets
Important: This page is general information about the Saudi regulatory environment, not regulatory or legal advice. Regulatory requirements change and vary by product. Nothing here should be relied on for a submission. Classification, dossier content, labelling and claims must be reviewed and approved by a qualified regulatory professional, and confirmed with the SFDA, before anything is filed or printed. Last reviewed August 2026.